278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer

• Victor Moreno,
• Ramaswamy Govindan,
• George Blumenschein,
• Siddhartha Devarakonda,
• Melissa Johnson,
• Carlos Bachier,
• Bernard Doger de Spéville,
• Vincent Lam,
• Natalie Hyland

Affiliations

Victor Moreno

Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) and CIBERESP, L'Hospitalet de Llobregat, Barcelona, Spain

Ramaswamy Govindan

Aff2 0000 0001 2355 7002grid.4367.6Division of OncologyWashington University 63110 St Louis MO USA

George Blumenschein

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Siddhartha Devarakonda

2Washington University School of Medicine, Saint Louis, MO, USA

Melissa Johnson

3Sarah Cannon Research Institute, Nashville, TN, USA

Carlos Bachier

7Sarah Cannon Center for Blood Cancer, Nashville, TN, USA

Bernard Doger de Spéville

4Fundación Jiménez Díaz Univ. Hospital, Madrid, Spain

Vincent Lam

1MD Anderson Cancer Center, Houston, TX, USA

Natalie Hyland

8Adaptimmune, Abingdon, UK